PetVivo (PETV) 10-Q 11 Feb 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2020	Feb. 10, 2021
Cover [Abstract]
Entity Registrant Name	PetVivo Holdings, Inc.
Entity Central Index Key	0001512922
Document Type	10-Q
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,795,666
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Current Assets
Cash and cash equivalents	$ 230,969	$ 888
Restricted cash		9,694
Accounts receivable	2,250	1,000
Inventory	9,971
Equity sale proceeds receivable		52,000
Investments - equity securities	1,500	1,500
Prepaid expenses - short term	141,687	132,023
Total Current Assets	386,377	197,105
Property and Equipment:
Property and equipment	339,917	221,493
Less: accumulated depreciation	(136,318)	(111,586)
Total Property and Equipment, net	203,599	109,907
Other Assets:
Operating lease right-of-use	164,350	148,693
Deferred offering costs	110,744
Trademark and patents, net	25,769	58,611
Security deposit	8,201	8,201
Total Other Assets	309,064	215,505
Total Assets	899,040	522,517
Current Liabilities
Accounts payable and accrued expenses	782,732	794,057
Accrued expenses - related party	9,615	252,607
Convertible notes and accrued interest payable	280,000
PPP loan - short term	33,364
Notes payable and accrued interest	40,969	15,095
Notes payable and accrued interest - related party	34,466	61,255
Operating lease liability - short term	26,450	24,791
Total Current Liabilities	1,207,596	1,147,805
Other Liabilities:
PPP loan (net of current)	5,561
Note payable and accrued interest - related party (net of current)	15,360
Share-settled debt obligation - related party, net of debt discount	194,579
Convertible notes and accrued interest payable		286,981
Operating lease liability (net of current)	137,900	123,901
Total Other Liabilities	353,400	410,882
Total Liabilities	1,560,996	1,558,687
Commitments and Contingencies
Stockholders' Equity (Deficit):
Preferred stock, par value $0.001, 20,000,000 shares authorized 0 and 0 shares outstanding at December 31, 2020 and March 31, 2020, respectively
Common stock, par value $0.001, 250,000,000 shares authorized 6,718,979 and 5,727,965 shares outstanding at December 31, 2020 and March 31, 2020, respectively	6,719	5,728
Common stock to be issued		52,000
Additional Paid-In Capital	57,119,733	53,494,747
Accumulated Deficit	(57,788,408)	(54,588,645)
Total Stockholders' Deficit	(661,956)	(1,036,170)
Total Liabilities and Stockholders' Deficit	$ 899,040	$ 522,517

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Mar. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	6,718,979	5,727,965
Common stock, shares outstanding	6,718,979	5,727,965

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues	$ 507	$ 500	$ 7,303	$ 500
Cost of Sales		2,145	350	5,990
Gross Profit (Loss)	507	(1,645)	6,953	(5,490)
Operating Expenses:
Sales and Marketing	24,484	77,109	106,745	85,057
Research and Development	30,265	4,768	30,265	11,900
Intangible Impairment	8,353	28,038	23,930	28,038
General and Administrative:
Depreciation and Amortization	12,398	137,725	73,062	422,855
Other General and Administrative	310,397	323,476	1,418,976	942,725
Total General and Administration	322,795	461,201	1,492,038	1,365,580
Total Operating Expenses	385,897	571,116	1,652,978	1,490,605
Operating Loss	(385,390)	(572,761)	(1,646,025)	(1,496,095)
Other Income (Expense)
Gain on Sale of Asset			482	450
Gain on Settlement		29,986		29,986
Gain on Debt Restructuring			516
Gain (Loss) on Debt Extinguishment	366,903		366,903	(81,738)
Derivative Expense	(970,600)		(1,702,100)
Interest Expense	(48,666)	(8,418)	(219,539)	(23,855)
Total Other Income (Expense)	(652,363)	21,568	(1,553,738)	(75,157)
Net Loss before taxes	(1,037,753)	(551,193)	(3,199,763)	(1,571,252)
Income Tax Provision
Net Loss	$ (1,037,753)	$ (551,193)	$ (3,199,763)	$ (1,571,252)
Net Loss Per Share - Basic and Diluted	$ (0.16)	$ (0.10)	$ (0.53)	$ (0.30)
Weighted Average Common Shares Outstanding - Basic and Diluted	6,442,549	5,525,011	6,006,382	5,170,499

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Common Stock to be Issued [Member]	Total
Balance at Mar. 31, 2019	$ 4,967	$ 51,569,795	$ (52,505,912)	$ 86,333	$ (844,817)
Balance, shares at Mar. 31, 2019	4,966,801
Stock-based compensation		157,134		33,667	190,801
Net loss			(500,887)		(500,887)
Balance at Jun. 30, 2019	$ 4,967	51,726,929	(53,006,799)	120,000	(1,154,903)
Balance, shares at Jun. 30, 2019	4,966,801
Balance at Mar. 31, 2019	$ 4,967	51,569,795	(52,505,912)	86,333	$ (844,817)
Balance, shares at Mar. 31, 2019	4,966,801
Common stock issued, shares					652,466
Net loss					$ (1,571,252)
Balance at Dec. 31, 2019	$ 5,619	53,183,545	(54,077,165)	139,891	(748,110)
Balance, shares at Dec. 31, 2019	5,619,267
Balance at Jun. 30, 2019	$ 4,967	51,726,929	(53,006,799)	120,000	(1,154,903)
Balance, shares at Jun. 30, 2019	4,966,801
Common stock issued	$ 19	119,881		(120,000)
Common stock issued, shares	19,425
Common stock sold	$ 90	99,910			100,000
Common stock sold, shares	90,000
Stock-based compensation	$ 8	135,270		102,000	237,278
Stock-based compensation, shares	7,574
Stock issued for debt conversion	$ 324	537,379			537,703
Stock issued for debt conversion, shares	323,967
Net loss			(519,173)		(519,173)
Balance at Sep. 30, 2019	$ 5,408	52,619,469	(53,525,972)	102,000	(799,095)
Balance, shares at Sep. 30, 2019	5,407,767
Balance at Jun. 30, 2019	$ 4,967	51,726,929	(53,006,799)	120,000	(1,154,903)
Balance, shares at Jun. 30, 2019	4,966,801
Balance at Dec. 31, 2019	$ 5,619	53,183,545	(54,077,165)	139,891	(748,110)
Balance, shares at Dec. 31, 2019	5,619,267
Balance at Sep. 30, 2019	$ 5,408	52,619,469	(53,525,972)	102,000	(799,095)
Balance, shares at Sep. 30, 2019	5,407,767
Common stock issued	$ 67	101,933		(102,000)
Common stock issued, shares	67,500
Common stock sold	$ 122	134,878		69,391	204,391
Common stock sold, shares	121,500
Warrants sold		34,609			34,609
Stock-based compensation	$ 22	292,656		70,500	363,178
Stock-based compensation, shares	22,500
Net loss			(551,193)		(551,193)
Balance at Dec. 31, 2019	$ 5,619	53,183,545	(54,077,165)	139,891	(748,110)
Balance, shares at Dec. 31, 2019	5,619,267
Balance at Mar. 31, 2020	$ 5,728	53,494,747	(54,588,645)	52,000	(1,036,170)
Balance, shares at Mar. 31, 2020	5,727,965
Common stock issued	$ 20	51,980		(52,000)
Common stock issued, shares	20,000
Warrants issued in conjunction with convertible debt		91,500			91,500
Stock-based compensation	$ 30	183,214			183,244
Stock-based compensation, shares	30,000
Net loss			(814,008)		(814,008)
Balance at Jun. 30, 2020	$ 5,778	53,821,441	(55,402,653)		(1,575,434)
Balance, shares at Jun. 30, 2020	5,777,965
Balance at Mar. 31, 2020	$ 5,728	53,494,747	(54,588,645)	52,000	$ (1,036,170)
Balance, shares at Mar. 31, 2020	5,727,965
Common stock issued, shares					991,014
Stock-based compensation					$ 889,597
Stock-based compensation, shares
Net loss					$ (3,199,763)
Balance at Dec. 31, 2020	$ 6,719	57,119,733	(57,788,408)		(661,956)
Balance, shares at Dec. 31, 2020	6,718,979
Balance at Jun. 30, 2020	$ 5,778	53,821,441	(55,402,653)		(1,575,434)
Balance, shares at Jun. 30, 2020	5,777,965
Common stock sold	$ 226	316,274			316,500
Common stock sold, shares	226,071
Stock-based compensation	$ 175	653,688			653,863
Stock-based compensation, shares	174,752
Stock issued for debt conversion	$ 25	25,357			25,382
Stock issued for debt conversion, shares	25,003
Cashless warrant exercises	$ 15	(15)
Cashless warrant exercises, shares	15,257
Net loss			(1,348,002)		(1,348,002)
Balance at Sep. 30, 2020	$ 6,219	54,816,745	(56,750,655)		(1,927,691)
Balance, shares at Sep. 30, 2020	6,219,048
Cash paid to exercise warrants	$ 202	449,791			449,993
Cash paid to exercise warrants, shares	202,499
1-for-4 reverse split rounding	$ 1	(1)
1-for-4 reverse split rounding, shares	724
Stock issued for debt conversion	$ 264	1,728,741			1,729,005
Stock issued for debt conversion, shares	263,568
Stock-based compensation - employees		52,490			52,490
Stock issued for services - non-employees		72,000			72,000
Cashless warrant exercises	$ 33	(33)
Cashless warrant exercises, shares	33,140
Net loss			(1,037,753)		(1,037,753)
Balance at Dec. 31, 2020	$ 6,719	$ 57,119,733	$ (57,788,408)		$ (661,956)
Balance, shares at Dec. 31, 2020	6,718,979

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)	Dec. 29, 2020	Oct. 23, 2020	Oct. 31, 2020	Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]
Reverse stock split, description	On December 29, 2020, the Company effected a reverse stock split of all its outstanding common stock at a ratio of 1-for-4 shares. Pursuant to this reverse stock split, each four (4) shares of PetVivo's outstanding common stock, $.001 par value per share, was combined and converted into one (1) post-split outstanding shares of common stock, $.001 par value per share. This reverse stock split affected all PetVivo shareholders uniformly and accordingly did not alter any shareholder's percentage interest or ownership of PetVivo equity. Through the date of this filing, 724 shares of common stock have been issued due to rounding up of fractional shares.	The Company approved and declared a reverse stock split of all its outstanding common stock at a ratio of 1-for-4 shares; this reverse stock split was made effective on December 29, 2020.	Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was made effective December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000; all share and per share data has been retroactively adjusted for this reverse split for all period presented.	1-for-4 reverse split

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss For The Period	$ (1,037,753)	$ (3,199,763)	$ (1,571,252)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Derivative expense	970,600	1,702,100
Stock-based compensation - employees		889,597	791,256
Stock issued for services - non-employees		72,000
Depreciation and amortization		73,062	422,855
Amortization of debt discount		173,174
Intangible impairment	8,353	23,930	28,038
Loss (Gain) on debt extinguishment	(366,903)	(366,903)	81,738
Gain on debt restructuring		(516)
Gain on settlement			(29,986)
Gain on sale of asset		(482)	(450)
Changes in Operating Assets and Liabilities
Increase in prepaid expenses and deferred offering costs		(120,408)	(166,270)
Increase in accounts receivable		(1,250)	(500)
Increase in inventory		(9,971)
Interest accrued on notes payable - related party		7,011	4,314
Interest accrued on notes payable		2,823
Interest accrued on convertible notes payable		37,150	18,537
Decrease in accounts payable and accrued expense		(10,924)	(23,471)
Increase (decrease) in accrued expenses - related party		(47,475)	30,053
Net Cash Used In Operating Activities		(776,845)	(415,138)
CASH FLOWS FROM INVESTING ACTIVITIES
Increase in investments			(1,500)
Sale of equipment		482	450
Purchase of equipment		(118,424)	(1,000)
Increase in patents and trademarks		(39,817)	(44,822)
Net Cash Used in Investing Activities		(157,759)	(46,872)
CASH FLOWS FROM FINANCING ACTIVITIES
Cash proceeds from common stock sold		316,500	339,000
Cash proceeds from warrant exercises		449,993
Equity sale proceeds receivable		52,000
Proceeds from PPP note payable		38,665
Proceeds from notes payable		27,500
Proceeds from convertible notes		322,500	280,000
Repayments of convertible notes		(28,077)	(11,479)
Repayments of notes payable	(1,531)	(4,190)	(18,831)
Repayments of notes payable - related party		(19,900)	(26,900)
Net Cash Provided by Financing Activities		1,154,991	561,790
Net Increase in Cash		220,387	99,780
Cash and Restricted Cash at Beginning of Period		10,582	6,460
Cash and Restricted Cash at End of Period	230,969	230,969	106,240
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash Paid During The Period For: Interest	$ 559	45,850	16,338
Cash Paid During The Period For: Stock granted for debt conversion		1,729,005
SUPPLEMENTAL DISCLOSURE ON NON-CASH FINANCING AND INVESTING ACTIVITIES
Derivative treated as debt discount		352,941	537,703
Share-settled debt obligation - related party debt modification		196,000
Notes payable - related party converted into common stock		$ 25,382

Summary of Significant Accounti

Summary of Significant Accounting Policies and Organization	9 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies and Organization	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota. (B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. In October 2020, the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was made effective December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000; all share and per share data has been retroactively adjusted for this reverse split for all period presented. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. Although these interim financial statements at December 31, 2020 and for the nine months ended December 31, 2020 and 2019 are unaudited, in the opinion of our management, such statements include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the nine months ended December 31, 2020 are not necessarily indicative of the results to be expected for the year ended March 31, 2021 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2020, included in our annual report on Form 10-K filed with the SEC on June 29, 2020. (C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation. (D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include collectability of accounts receivable, estimated useful lives and potential impairment of property and equipment and intangible assets, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, estimate of fair value of lease liabilities and related right of use asset, valuation of deferred tax assets and valuation of in-kind contribution of services and interest. (E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2020, the Company had $230,969 in cash and no cash equivalents. At March 31, 2020, the Company had $10,582 in cash and restricted cash and no cash equivalents. (F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed limits insured by the Federal Deposit Insurance Corporation (FDIC). At December 31, 2020, cash did not exceed the FDIC uninsured balances and management believes the Company is not exposed to any significant credit risk on cash. (G) Property & Equipment Property and equipment are recorded at cost less accumulated depreciation. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after taking into account their respective estimated residual values) over the asset’s estimated useful life of (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures. (H) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60 months or the life of the patent. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. (I) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 1,124,803 warrants outstanding as of December 31, 2020 with varying exercise prices ranging from $1.20 to $15.56/share. The weighted average exercise price for these warrants is $1.99/share. These warrants are excluded from the weighted average number of shares because they are considered anti-dilutive. The Company had 1,305,111 warrants outstanding as of December 31, 2019, with varying exercise prices ranging from $1.20 to $15.56/share. The weighted average exercise price for these warrants was $2.16/share. These warrants are excluded from the weighted average number of shares because they are considered antidilutive. The Company uses the guidance in ASC 260 to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive. At December 31, 2020, the Company had $280,000 in convertible notes principal and $-0- in interest outstanding; at December 31, 2019, the Company had $280,000 in convertible notes principal and $7,057 in interest outstanding; these notes mature in our fiscal quarter ended June 30, 2021. If converted, the $280,000 in outstanding principal and $-0- in accrued interest would convert into 96,924 shares of common stock at a rate of $2.89 per share. Also at December 31, 2020, the Company had a share-settled debt obligation with a related party wherein $196,000 in principal will be converted into units of one share of common stock and one warrant for a share of common stock with the exact number of units to be determined by the terms of an S-1 offering that as of this filing has yet to take place. See Note 8 to these financial statements for more information on the convertible notes discussed in this paragraph. (J) Revenue Recognition The Company recognizes revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers.” Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company adopted the guidance on April 1, 2018 using the cumulative catch-up transition method. This change in accounting did not have any material effect on the Company’s financial statements. The Company recognizes revenue related to our sales of Kush product to veterinarians when the performance obligation is met, which is when we have received an order and shipped the Kush product. (K) Research and Development The Company expenses research and development costs as incurred. (L) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements,” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of investments – equity securities receivable, notes payable and accrued interest, notes payable and accrued interest - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2020 and March 31, 2020, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company measured its investments – equity securities receivable at fair value at December 31, 2020, and March 31, 2020, see Note 4 to the financial statements included in this Form 10-Q. The Company accounts for derivative instruments in accordance with Accounting Standards Codification 815, Derivatives and Hedging (“ASC 815”), which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities. ASC 815 requires that an entity recognize all derivatives as either assets or liabilities in the balance sheet and measure those instruments at fair value, which are in level 3 of the fair value hierarchy. If certain conditions are met, a derivative may be specifically designated as a hedge, the objective of which is to match the timing of gain or loss recognition on the hedging derivative with the recognition of (i) the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk or (ii) the earnings effect of the hedged forecasted transaction. For a derivative not designated as a hedging instrument, the gain or loss is recognized in income in the period of change. (M) Stock-Based Compensation – Employees and Non-Employees Equity Instruments Issued to Employees and Non-Employees for Acquiring Goods or Services On June 20, 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (for example, service providers, external legal counsel, suppliers, etc.). Under the new standard, companies will no longer be required to value non-employee awards differently from employee awards. Meaning that companies will value all equity classified awards at their grant-date under ASC 718 and forgo revaluing the award after this date. The Company accounts for employee stock-based compensation the same as non-employee stock-based compensation. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. (N) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. As required by ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied ASC Topic 740 to all tax positions for which the statute of limitations remained open. As a result of the implementation of ASC Topic 740, the Company did not recognize any change in the liability for unrecognized tax benefits. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses. (O) Inventory Inventories are recorded in accordance with ASC 330 and are stated at the lower of cost and net realizable value. We account for inventories using the first in first out (FIFO) methodology and capitalize costs on a project basis as they occur. The current marketed shelf life of our Kush inventory is 3 years. However, management reserves the right to review and adjust this as appropriate. (P) Recently Issued and Adopted Accounting Pronouncements In January 2017, the FASB issued ASU No. 2017-04, “Intangibles and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates the requirement to calculate the implied fair value of goodwill, but rather requires an entity to record an impairment charge based on the excess of a reporting unit’s carrying value over its fair value. This amendment is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We adopted this ASU on April 1, 2020 and it did not have a material effect on our consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements on fair value measurements in Topic 820. The ASU is effective for the Registrants for fiscal years beginning after December 15, 2019, and interim periods therein. The Company adopted this ASU on April 1, 2020 and it did not have a material impact on the financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Going Concern

Going Concern	9 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 - GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company incurred net losses of $3,199,763 for the nine-month period ended December 31, 2020 and had net cash used in operating activities of $776,845 for the same period. Additionally, the Company has an accumulated deficit of $57,788,408, working capital deficit of $821,219, and a stockholders’ deficit of $661,956 at December 31, 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months after the date of issuance on these consolidated financial statements. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to achieve a level of profitability and/or to obtain adequate financing through the issuance of debt or equity in order to finance its operations. Management intends to raise additional funds through a private placement or public offering of its equity securities; this is evidenced by the filing of Forms S-1 and S-1/A with the Securities and Exchange Commission on October 13, 2020, and December 31, 2020, respectively. Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern. While the Company believes in its viability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and raise additional funds. COVID-19 has had an impact on the global economy, which directly or indirectly may have an impact on our ability to continue as a going concern. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Lease and Commitments

Lease and Commitments	9 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Lease and Commitments	NOTE 3 – LEASE AND COMMITMENTS Rent expense for the three-month periods ended December 31, 2020 and December 31, 2019 were $13,343 and $13,434, respectively. Rent expense for the nine-month periods ended December 31, 2020 and December 31, 2019 were $40,479 and $37,679, respectively. The Company entered into an eighty-four-month lease for 3,577 square feet of newly constructed office, laboratory and warehouse space located in Edina, Minnesota on May 3, 2017. The Company resided in the facility starting in November of 2017. The base rent started as $2,078 per month with 2% increases annually and the Company is responsible for its proportional share of common space expenses, property taxes, and building insurance. The base rent as of December 31, 2020 is $2,162. This lease is terminable by the landlord if damage causes the property to no longer be utilized as an integrated whole and by the Company if damage causes the facility to be unusable for a period of 45 days. On January 8 th The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of December 31, 2020: Year Ended March 31, 2021 $ 6,614 2022 26,634 2023 27,167 2024 27,710 2025 28,265 Thereafter 48,305 $ 164,695 Less: Amount representing interest (345 ) Present value of lease liabilities $ 164,350 In compliance with ASC 842 the Company recognized, based on the extended lease term to November 2026 and a treasury rate of 0.12%, an operating lease right-to-use assets for approximately $189,600 and corresponding and equal operating lease liabilities for the lease of our facility in Edina, MN. As of December 31, 2020, the Company only had one operating lease so that the remaining lease term and weighted average discount rate are approximately 6 years and 0.12%, respectively. December 31, 2020 Present value of future base rent lease payments $ 164,350 Base rent payments included in prepaid expenses - Present value of future base rent lease payments – net $ 164,350 As of December 31, 2020, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: December 31, 2020 Operating lease right-of-use asset $ 164,350 Total operating lease assets 164,350 Operating lease current liability 26,450 Operating lease other liability 137,900 Total operating lease liabilities $ 164,350 Pursuant to a lease wherein our subsidiary, Gel-Del Technologies, Inc., was the lessee until and through the lease's termination in fiscal year 2017-2018, the Company had recorded as of those fiscal years approximately $330,000 as a potential payable to the lessor, which this liability remains as of December 31, 2020 and is included in accounts payable.

Investments - Equity Securities

Investments - Equity Securities	9 Months Ended
	Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Investments - Equity Securities	NOTE 4 – INVESTMENTS – EQUITY SECURITIES On June 28, 2019, the Company entered into a purchase agreement with a third-party to purchase 1,500,000 shares of Emerald Organic Products, Inc. (OTC Pink: “EMOR”) common stock for consideration of $1,500. The Company applied guidance from ASU No. 2016-01 Financial Instruments – Overall – Recognition and Measurement of Financial Assets and Financial Liabilities and ASC 820 to arrive at a fair value at December 31, 2020 of $1,500. The Company took into account many factors when determining the stock’s fair value including, but not limited to, the nature and duration of the restriction on the stock, the extent to which potential buyers would be limited by the restriction, and qualitative and quantitative factors specific to both the instrument and the issuer and risk of non-performance.

Prepaid Expenses and Deferred O

Prepaid Expenses and Deferred Offering Costs	9 Months Ended
	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Deferred Offering Costs	NOTE 5 – PREPAID EXPENSES AND DEFERRED OFFERING COSTS At December 31, 2020 and March 31, 2020, the Company had $252,431 and $132,023 in prepaid expenses and deferred offering costs, respectively. At December 31, 2020 the total prepaids amount of $252,431 was made up primarily of $141,687 in prepaid expenses – short term and $110,744 in deferred offering costs. Of the $141,687 classified as prepaid expenses – short term, approximately $73,000 is made up of advertising and marketing services yet to be performed, and $25,000 is made up of a deposit for our canine elbow osteoarthritis study to be performed by Colorado State University. The $110,744 classified as deferred offering expenses is entirely made up of legal costs incurred related to our S-1 and S-1/A filings with the Securities and Exchange Commission on October 13, 2020, and December 31, 2020, respectively, and will be recorded as a reduction of proceeds should we be successful in raising capital through this S-1 offering or expensed if not.

Property and Equipment

Property and Equipment	9 Months Ended
	Dec. 31, 2020
Property and Equipment:
Property and Equipment	NOTE 6 – PROPERTY AND EQUIPMENT The components of property and equipment were as follows: December 31, 2020 March 31, 2020 Leasehold improvements $ 177,184 $ 98,706 Furniture and office equipment 10,130 10,130 Production equipment 127,419 87,473 R&D equipment 25,184 25,184 Total, at cost 339,917 221,493 Accumulated depreciation (136,318 ) (111,586 ) Total, net $ 203,599 $ 109,907 During the three months ended December 31, 2020 and 2019, depreciation expense was $10,768 and $2,438, respectively. During the nine months ended December 31, 2020 and 2019, depreciation expense was $24,731 and $12,861, respectively. During the nine months ended December 31, 2020, the Company received cash proceeds in the amount of $482 related to an insurance claim processed during the three months ended March 31, 2020 for our modular cleanroom that was damaged during shipment to the buyer of the same. During the nine months ended December 31, 2019, the Company recognized $450 gain on sale of asset related to the sale of a piece of equipment that was originally purchased for $1,004, was fully depreciated at the time of the sale, and was sold for $450 in cash.

Trademarks and Patents, Net

Trademarks and Patents, Net	9 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Trademarks and Patents, Net	NOTE 7 – TRADEMARKS AND PATENTS, NET The components of intangible assets, all of which are finite-lived, were as follows: December 31, 2020 March 31, 2020 Patents $ 3,836,911 $ 3,822,542 Trademarks 26,142 25,023 Total, at cost 3,863,053 3,847,565 Accumulated Amortization (3,837,284 ) (3,788,954 ) Total, net $ 25,769 $ 58,611 During the three-month periods ended December 31, 2020 and 2019, amortization expense was $1,629 and $134,283, respectively. During the nine-month periods ended December 31, 2020 and 2019, amortization expense was $48,331 and $408,994, respectively. During the three-month periods ended December 31, 2020 and 2019, intangible impairment expense was $8,353 and $28,038, respectively. During the nine-month periods ended December 31, 2020 and 2019, intangible impairment expense was $23,930 and $28,038, respectively.

Notes Payable and Convertible N

Notes Payable and Convertible Notes	9 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes Payable and Convertible Notes	NOTE 8 – NOTES PAYABLE AND CONVERTIBLE NOTES At December 31, 2020, the Company is obligated for $129,720 in notes payable, notes payable – related parties and accrued interest and $280,000 in convertible notes payable. At March 31, 2020, the Company is obligated for $76,350 in notes payable and accrued interest and $286,981 in convertible notes payable and accrued interest. December 31, 2020 March 31, 2020 Notes Payable Convertible Notes Payable Notes Payable Convertible Notes Payable 1. Third Parties – Principal $ 79,634 $ 280,000 $ 15,000 $ 280,000 Third Parties – Interest 260 - 95 6,981 Third Parties – Total 79,894 280,000 15,095 286,981 2. Related Parties – Principal 49,826 - 59,642 - Related Parties – Interest - - 1,613 - Related Parties – Total 49,826 - 61,255 - Total $ 129,720 $ 280,000 $ 76,350 $ 286,981 Convertible Notes Payable The Company entered into a convertible note payable held by RedDiamond Partners, LLC (“RDCN”) on June 15, 2020, whereby the RDCN was convertible on or after January 15, 2021 and before maturity on March 15, 2021 at a rate of $1.12/share. The RDCN was issued in the principal amount of $352,941 with $52,941 being made up of a 15% Original Issue Discount (“OID”) and included a conversion feature. However, this conversion feature’s exercise contingency was only utilizable if triggered by the occurrence of an Event of Default, which included events that were outside the control of the Company (i.e. not based solely on the market for the Company’s stock or the Company’s own operations). Additionally, the RDCN accrued interest at a rate of 12.5% per annum, calculated on a 360-day-per-year-basis. This RDCN was issued alongside a warrant for purchase of 139,286 shares of Company common stock (“RDCN Warrants”) with a relative fair value of $91,500. Upon inception, the outstanding principal balance of the RDCN was reduced to $-0- by various discounts on the debt totaling ($352,941) as follows: i) the RDCN Warrants generated a discount on the debt of ($91,500) based on the relative fair value of the same; ii) $2,500 in investor legal costs was treated as a discount on the debt of ($2,500) since this was paid by the Company; iii) $52,941 of OID was treated as a discount on the debt of ($52,941); iv) a discount of ($206,000) was taken due to the conversion option being treated as a derivative. In evaluating the various instruments and their components within this transaction (including issuance of the RDCN and RDCN Warrants) for treatment as a derivative and the respective accounting treatment of the same, the Company referenced ASC 470 and ASC 815 in conjunction with interpretive guidance. In conjunction with the RDCN and RDCN Warrants issuances, the Company also paid $30,000 and issued 75,000 warrants (“Think Warrants”) valued at $31,500 using the Black-Scholes model to Think Equity for soliciting the RedDiamond Partners, LLC transaction. The total issuance costs paid to Think Equity of $61,500 of cash and warrants, which the Company recorded the relative fair value of $52,399 to expense since no further discount was available to be taken on the debt. As of December 31, 2020, the Company had $-0- in unamortized debt discount remaining and owed $-0- in principal and interest pursuant to the RDCN. For the three and nine months ended December 31, 2020, the Company amortized a pro-rata portion of the discount on the debt on a straight-line basis to interest expense in the amounts of $35,919 and $173,174, respectively. At October 26, 2020, the Company entered into a note conversion agreement that converted the then outstanding balance of $368,995 made up of $352,941 in principal and $16,054 in accrued interest into 263,568 shares of common stock at a rate of $1.40 per share when the market price of the stock was $6.56. The settlement relieved a derivative liability in the amount of $1,908,100, outstanding principal and interest of $368,995, and debt discount in the amount of ($181,187) in exchange for stock valued on the date of the settlement in the total amount of $1,729,005; this triggered a gain on debt extinguishment of $366,903. Please see Note 10 to these financial statements for more information on this conversion. At December 31, 2020 and March 31, 2020, the Company is/was obligated for several convertible notes payable held by accredited investors (“Accredited Investor Convertible Notes” or “AICN” or “AICNs”). At December 31, 2020 the total outstanding balance of these AICNs of $280,000 was made up of $280,000 in principal and $-0- in accrued interest. At March 31, 2020, the total outstanding balance of these AICNs of $286,981 was made up of $280,000 in principal and $6,981 in accrued interest. The Company entered into these AICNs during the quarter ended June 30, 2019. All of these AICNs mature during the quarter ended June 30, 2021, two years from their inception dates. These AICNs accrue interest at a rate of 10% annually. Accrued interest is due and payable each calendar quarter in cash. During the three and nine months ended December 31, 2020, the Company paid out $14,115 and $28,077, respectively, in accrued interest to these convertible note holders. During the three and nine months ended December 31, 2019, the Company paid out $-0- and $11,479, respectively, in accrued interest to these convertible note holders. These AICNs automatically convert into shares of common stock at a rate of $2.89 per share at the earlier of the maturity date or an uplist to a national securities exchange (e.g. NASDAQ or New York Stock Exchange) provided that the Company’s stock price is at least $3.47 at the time of the uplist. The AICN note holders have the right to convert their outstanding principal and interest into shares of the Company’s common stock at any time during their note’s term at $2.89 per share. No AICN note holders have converted their notes as of December 31, 2020. Convertible Notes Payable – Related Party At December 31, 2020 and March 31, 2020, the Company was not obligated for any related party convertible notes payable principal and accrued interest. However, the Company entered into notes payable with three directors on May 14, 2020, in the aggregate principal amount of $25,000. The notes with these three directors accrued interest at a rate of 6% annually, yielding a total amount of accrued interest of $382 at August 14, 2020, the maturity date, and on that date the total outstanding balance of $25,382 was converted at $1.02 per share into 25,003 shares of common stock valued at $25,383. Notes Payable On January 8 th At December 31, 2020, the Company was obligated for notes payable and accrued interest in the amounts of $40,969 and $-0-, respectively. At March 31, 2020, the Company was obligated for notes payable and accrued interest in the amounts of $15,000 and $95, respectively. During the three months ended December 31, 2020, the Company paid $559 in interest and $1,531 in principal pursuant to this note payable. PPP Loan Payable On May 1, 2020, the Company received $38,665 in loan proceeds pursuant to the Paycheck Protection Program enacted by the 2020 US Federal government Coronavirus Aid, Relief, and Economic Security Act. At December 31, 2020, the Company was obligated for the outstanding balance of $38,925, made up of $38,665 in principal and $260 in accrued interest. The principal and accrued interest may be forgivable and the Company has applied for forgiveness. The loan accrues interest at a rate of 1% per annum and matures on May 1, 2022; if not forgiven prior to December 1, 2020, the Company is required to pay monthly installments toward principal and interest until the note is paid in full. However, through the date of this filing we are awaiting review and further guidance from the loan issuer on our repayment status. Notes Payable – Related Party At December 31, 2020 and March 31, 2020, the Company was obligated for related party notes payable and accrued interest in the total amount of $49,826 and $61,255, respectively. The balance of $49,826 outstanding at December 31, 2020, is described as the Amendment to Promissory Note in the below Note 9 to these financial statements.

Share-settled Debt Obligation -

Share-settled Debt Obligation - Related Party	9 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Share-settled Debt Obligation - Related Party	NOTE 9 – SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY At December 31, and March 31, 2020, respectively, the Company is obligated for $194,579 in share-settled debt obligation – related party made up of $196,000 in principal owed and ($1,421) in discount on the debt. During the three and nine months ended December 31, 2020 the Company amortized $1,421 in debt discount to interest expense. Effective September 1, 2020, the Company entered into two debt settlement agreements with David B. Masters, a director of the Company, pursuant to an Amendment to Promissory Note and a Promissory Note. The Amendment to Promissory Note extends, for up to an additional two years and under the same terms as originally entered into, the original promissory notes which were issued by Gel-Del Technologies, Inc., a wholly owned subsidiary of the Company, to Dr. Masters. Because this Amendment to Promissory Note simply extended the term over which the Company is required to pay back the outstanding balance this change has been treated as a debt modification. The outstanding principal of $59,642 and interest balance of $6,058 of the original promissory notes was $65,700 at the time of execution of the Amendment to Promissory Note; the terms of this Amendment to Promissory Note are interest accrual at a rate of 8% on an annual basis or 20% if the note is in default. The Amendment to Promissory Note requires monthly payments of $3,100 and a maturity date of June 30, 2022 provided however that if the Company shall achieve $1,500,000 in equity sales or achieve gross product sales of $1,500,000, the Company must pay the outstanding balance at that time. The Promissory Note was entered into with an effective date of September 1, 2020 in a principal amount of $195,000, which represented David Masters’ release of any claim to the $195,000 in past accrued salary he was owed, it accrues interest at a rate of 3% per annum, has a maturity date of August 31, 2022, and required payments of $4,000 per month beginning when the Company’s sale of products reach $3,500,000. The reclassification of the $195,000 was treated as a debt modification. A Settlement and General Release (“ Settlement Agreement On October 15, 2020, the Company entered into a note conversion agreement with David Masters whereby the Company and Mr. Masters both agreed to convert his note payable in the then outstanding balance of $193,158 made up of $192,500 in principal and $658 in accrued interest into common stock and warrants pursuant to terms identical to what is agreed upon in our S-1 offering currently being conducted. Pursuant to this conversion agreement the Company agreed to convert $196,000 made up of $192,500 in principal and a conversion fee of $3,500 and Mr. Masters agreed to forego the interest accrued in the amount of $658. The conversion fee of $3,500 was treated as a discount on the debt and the $658 was treated as a reduction of the discount on debt. Therefore, upon inception the convertible balance of $196,000 was reduced by a discount on the debt of 2,842. As of December 31, 2020, the outstanding balance of this share-settled debt obligation had not yet been converted and is recorded as a liability due to the fact the Company had not agreed to terms of our S-1 offering currently being conducted. At December 31, 2020, the Company was obligated for principal and accrued interest in the amounts of $-0- and $-0-, respectively, related to the Promissory Note and $49,826 and $-0-, respectively, related to the Amendment to Promissory Note.

Derivative Liability and Expens

Derivative Liability and Expense	9 Months Ended
	Dec. 31, 2020
Derivative Liability [Abstract]
Derivative Liability and Expense	NOTE 10 – DERIVATIVE LIABILITY AND EXPENSE The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operation as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. The Company used the following assumptions for determining the fair value of the conversion feature in the RDCN referenced in Note 8 to these consolidated financial statements, under the binomial pricing model at June 15, 2020, September 30, 2020, and October 26, 2020, the issuance, balance sheet, and conversion dates, respectively: June 15, 2020 September 30, 2020 October 26, 2020 Stock price on valuation date $ 1.68 $ 1.60 $ 6.56 Conversion price $ 1.12 $ 1.12 $ 1.12 Days to maturity 273 166 140 Weighted-average volatility* 367 % 327 % 197 % Risk-free rate .18 % .12 % .11 % The initial valuation of $526,800 at June 15, 2020, generated a discount on the debt of $206,000, which net the convertible note liability to $-0- and forced a recognition of derivative expense of $320,800 and a corresponding offset to derivative liability of $526,800. At September 30, 2020, the Company revalued the derivative liability to $937,500. At October 26, 2020, the Company revalued the derivative liability to $1,908,100. For the three months ended December 31, 2020 and 2019, the Company recognized $970,600 and $-0- to derivative expense, respectively. For the nine months ended December 31, 2020 and 2019, the Company recognized $1,702,100 and $-0- to derivative expense and derivative liability, respectively. On October 26, 2020, the Company entered into a conversion agreement whereby the RDCN was converted into 263,568 shares of common stock at a rate of $1.40 per share; this triggered a gain on extinguishment of debt in the amount of $366,903 as described in these financial statements’ Note 8. The Company recorded derivative liability transactions during the nine-month period ended December 31, 2020 as follows: Nine Months Ended December 31, 2020 Convertible note embedded derivative liability Balance at March 31, 2020 $ -0- Initial recognition of derivative liability 526,800 Change in fair value 21,400 Balance at June 30, 2020 $ 548,200 Change in fair value 389,300 Balance at September 30, 2020 $ 937,500 Change in fair value 970,600 Balance at October 26, 2020 $ 1,908,100 Conversion of note on October 26,2020 (1,908,100 ) Balance at December 31, 2020 $ -0-

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 11 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES At December 31, 2020 and March 31, 2020, the Company is obligated to pay $782,732 and $794,057, respectively, in accounts payable and accrued expenses. Of the total at December 31, 2020, $555,960 is made up of accounts payable, while the $226,722 in accrued expenses mainly made up of past employee’s accrued salaries and related payroll taxes payable. Of the total at March 31, 2020 of $794,057, $556,653 is made up of accounts payable, while the $237,404 in accrued expenses is made up of past employee’s accrued salaries and related payroll taxes payable. The potential payroll taxes owed are not due until the accrued compensation has been paid. Since the Company has not paid these accrued wages, the Company has appropriately left the potential payroll taxes associated with these accrued wages unpaid. The Company has established an accrued liability for the potential taxes of approximately $14,198 and $22,025 at December 31, 2020 and March 31, 2020, respectively.

Accrued Expenses - Related Part

Accrued Expenses - Related Party	9 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued Expenses - Related Party	NOTE 12 – ACCRUED EXPENSES – RELATED PARTY At December 31, 2020, the Company is obligated to pay $9,615 in accrued expenses due to related parties. The total amount is made up of paid time off accrued and owed to both John Lai and John Carruth in equal amounts of $4,807. During the quarter ended December 31, 2020, David Masters signed a settlement and general release giving up any right to his $195,000 in accrued salary – related party. In exchange for this settlement and general release, the Company granted David Masters a note with a principal amount of $195,000, which is described further in this Form 10-Q’s Note 9. At March 31, 2020, the Company was obligated to pay $252,607 in accrued expenses due to related parties. Of the total, $38,954 was made up of accounts payable, while $213,653 is made up of accrued salaries and potential payroll taxes payable.

Common Stock and Warrants

Common Stock and Warrants	9 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Common Stock and Warrants	NOTE 13 - COMMON STOCK AND WARRANTS On October 23, 2020, the Company approved and declared a reverse stock split of all its outstanding common stock at a ratio of 1-for-4 shares; this reverse stock split was made effective on December 29, 2020. All references to number of shares and price per share data have been retroactively adjusted for this reverse stock split for all periods presented. Equity Incentive Plan On July 10, 2020, our Board of Directors unanimously approved the PetVivo Holdings, Inc “2020 Equity Incentive Plan” (the “2020 Plan”), subject to approval by our stockholders at the Regular Meeting of Stockholders held on September 22, 2020, when it was approved by our stockholders and became effective. The number of shares of our common stock available and that may be issued as awards under the 2020 Plan is 1,000,000 shares. Unless sooner terminated by the Board, the 2020 Plan will terminate at midnight on July 10, 2030. Eligible Participants Administration Shares Available for Awards ● the maximum aggregate number of shares of Common Stock granted as an Award to any Non-Employee Director in any one Plan Year will be 10,000 shares; provided that such limit will not apply to any election of a Non-Employee Director to receive shares of Common Stock in lieu of all or a portion of any annual Board, committee, chair or other retainer, or any meeting fees otherwise payable in cash. Types of Awards The 2020 Plan permits the following types of awards: stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, other stock-based awards, and dividend equivalents. As of December 31, 2020, the Company has not awarded any shares pursuant to the 2020 Plan. Common Stock On December 29, 2020, the Company effected a reverse stock split of all its outstanding common stock at a ratio of 1-for-4 shares. Pursuant to this reverse stock split, each four (4) shares of PetVivo’s outstanding common stock, $.001 par value per share, was combined and converted into one (1) post-split outstanding shares of common stock, $.001 par value per share. This reverse stock split affected all PetVivo shareholders uniformly and accordingly did not alter any shareholder’s percentage interest or ownership of PetVivo equity. Through the date of this filing, 724 shares of common stock have been issued due to rounding up of fractional shares. During the nine-month period ended December 31, 2020 the Company issued 991,014 shares of common stock as follows: i) 30,000 shares valued at $40,680 and recorded in Stock-based compensation to a service provider for video marketing services over a 6-month term; ii) 20,000 shares with a relative value of $34,709 pursuant to a purchase of 20,000 units whereby a unit is made up of 1 share of common stock and ½ warrant. The value of $34,709 along with the relative value of the warrants associated with this transaction of $17,291 ($52,000 total) was recorded during the quarter ended March 31, 2020 to Common Stock Subscribed and moved to Additional Paid in Capital and Capital Stock upon receipt of funds and issuance of shares of common stock during the quarter ended June 30, 2020; iii) 12,500 shares valued at $22,000 on July 1, 2020 to two service providers as follows: a) 10,000 to a marketing and investor relations service provider valued at $17,600 that was recorded to stock-based compensation; and b) 2,500 to a legal service provider valued at $4,400 that was recorded to stock-based compensation; iv) 15,257 shares valued at $12,053 on July 24, 2020 to one warrant holder whereby this warrant holder converted on a cashless basis 25,000 warrants into 15,257 shares of common stock and the warrant had an exercise price of $1.20 per share; v) 226,071 shares during August and September of 2020 in exchange for $316,500 in cash to four accredited investors; vi) 162,252 shares valued at $486,755 to directors and officers on September 14, 2020 as bonuses for work over the past two years and recorded to stock-based compensation as follows: a. 33,619 to John Lai b. 26,217 to John Carruth c. 22,993 to John Dolan d. 10,789 to Gregory Cash e. 10,711 to David Deming f. 10,627 to Robert Rudelius g. 10,550 to Randy Meyer h. 9,302 to Jim Martin i. 9,300 to Scott Johnson j. 9,209 to Joseph Jasper k. 8,935 to David Masters vii) 25,003 shares valued at $25,383 to three directors on August 14, 2020, pursuant to their conversions of notes in the total outstanding balance amount of $25,382 made up of $25,000 in principal and $382 in accrued interest; these notes had a set conversion price of $1.02 per share. viii) 263,568 shares in October of 2020 pursuant to conversion of $368,995 in principal and accrued interest of the RDCN valued at $1,729,005 as outlined in this Form 10-Q’s Note 8; ix) 32,347 shares in October of 2020 pursuant to John Lai’s cashless exercise of a warrant for purchase of 42,188 shares of common stock at a strike price of $1.33/sh; x) 202,499 shares in October, November and December to 20 accredited investors pursuant to their exercising of warrants with strike prices of $2.22 for cash proceeds of $449,993 recorded to cash paid to exercise warrants; and xi) 793 shares in October of 2020 pursuant to a warrant holder’s cashless exercise of a warrant for purchase of 6,750 shares of common stock at a strike price of $4.44/sh. During the nine months ended December 31, 2019, the Company issued 652,466 shares of common stock as follows: i) 87,000 shares to John Lai pursuant to a Settlement Agreement whereby Mr. Lai agreed to release the Company of all claims through the date of the agreement, September 11, 2019, including accrued compensation he had earned in the amount of $116,000 and hold the shares for a period of at least 3 years; ii) 143,952 shares to Randall Meyer pursuant to a Settlement Agreement whereby Mr. Meyer agreed to release the Company of all claims through the date of the agreement, September 11, 2019, including accrued compensation he had earned in the amount of $191,936 and hold the shares for a period of at least 3 years; iii) 51,000 shares to John Dolan pursuant to a Settlement Agreement whereby Mr. Dolan agreed to release the Company of all claims through the date of the agreement, September 11, 2019, including accrued compensation he had earned in the amount of $68,000 and hold the shares for a period of at least 3 years; and iv) 42,014 shares to a former employee pursuant to a Settlement Agreement dated August 29, 2019, whereby this individual agreed to release the Company of all claims, including compensation earned in the amount of $80,029; and v) 27,000 shares valued at $120,000 to a service provider for production services provided during the one-year period ended July 13, 2019 and recognized over that period on a pro-rata basis; and vi) 90,000 shares on September 13, 2019, to one shareholder that the Company sold in exchange for $100,000; vii) 67,500 shares valued at $102,000 to a service provider on September 18, 2019, in exchange for 12 months of video production and marketing services; viii) 121,500 shares to various accredited investors in exchange for $135,000 in cash, which equates to a price per share of $.28/share; ix) 22,500 shares to service providers for investor relations services to be performed by Barry Kaplan Associates during the six-month period ending in April 2020; x) On December 9, 2019, the Company entered into an agreement whereby we agreed to issue 37,500 shares of common stock to a service provider, Launchpad IR, at $1.68/share for total consideration of $70,500, for investor relations services. These shares remained unissued at the balance sheet date, December 31, 2019; xi) On December 31, 2019, the Company received $104,000 in exchange for 40,000 units, which equates to $2.60/unit, whereby a unit is made up of one share of common stock and ½ warrant share wherein the common stock was recorded at its relative fair value of $69,391 and the warrants are described below in this Note 13’s “Warrants” subsection. These shares remained unissued at the balance sheet date, December 31, 2019. On October 31, 2019, the Company’s Board of Directors also approved a compensation plan for John Lai that included his retention of 150,000 escrowed shares that he never returned to the Company’s Treasury. John Lai (CEO, President & Director), Randall Meyer (Director), and John Dolan (Secretary & Director) are all related parties, and the reduction of $375,936 as outlined in the above Roman numerals i through iii was included in Accrued Expenses – Related Party. The settlement of $80,029 for a former employee’s accrued salary as outlined in the above Roman numeral iv was accounted for as a reduction of Accounts Payable and Accrued Expenses. A loss on extinguishment of debt was recorded in the amount of $81,738 related to these transactions as indicated in Roman numerals i through iv above. Warrants During the nine-month period ended December 31, 2020, the Company granted warrants to purchase a total of 240,632 shares of common stock valued at $443,098, including: i) warrants for 10,000 shares, valued at $17,291 using the Black-Scholes model, to one investor, whereby the value was recorded during the quarter ended March 31, 2020 to Common Stock Subscribed and moved to Additional Paid in Capital upon receipt of funds and issuance of warrants on April 6, 2020, and further whereas the warrants vested immediately upon issuance and are exercisable at $4.00 per share for 3 years from the grant date of April 6, 2020; ii) warrants for 72,596 shares, valued at $160,307 using the Black-Scholes model, to directors, officers and consultants at prices between $1.40 and 1.60 per share with a weighted average price per share of $1.52 per share; and iii) warrants for 158,036 shares, valued at $265,500 using the Black-Scholes model, to an investor and broker, whereby the relative value as described in Note 9 of $91,500 was recorded to Warrants issued in conjunction with convertible debt on the statement of equity; the warrants have a cashless warrant exercise feature, are exercisable at $1.40 per share for a term of five years from the date of the grant of June 15, 2020 and vested immediately. These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: i) an expected volatility of the Company’s shares on the date of the grants of between approximately 350% and 433%, based on historical volatility. ii) risk-free rates identical to the U.S. Treasury 3-year and 5-year treasury bill rates on the date of the grants between 0.29% and 1.16%. During the nine months ended December 31, 2019, the Company granted warrants to purchase a total of 433,633 shares of common stock valued at $914,730 including: i) warrants for 413,633 shares, valued at $880,121 to directors and officers that vested immediately and over terms ending October 2022, and are exercisable over five-year terms between $1.33 and 2.22 per share; and viii) warrants for 20,000 shares, issued as a detachable warrant in purchased units with a relative fair value of $34,609, whereby an accredited investor purchased 40,000 units for $104,000 at a rate of $2.60/unit and a unit equates to one share of common stock and one-half warrant, and furthermore where the warrants are exercisable for a term of 3 years, have a strike price of $4.00/share and vested immediately. These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: i) an expected volatility of the Company’s shares on the date of the grants ranging between approximately 313% and 361%, which was arrived at by taking the number of trading days during the year ended on the date of the grant multiplied by the standard deviation of the percentage change in the closing market price on a day-by-day basis; and ii) a risk-free rate identical to the U.S. Treasury 13-week treasury bill rate on the date of the grants between 2.30% and 1.51%. During the nine months ended December 31, 2019, the Company cancelled 81,000 warrants to purchase a total of 81,000 shares of common stock including: i) warrants for 67,500 shares, valued at $300,770 using the Black-Scholes model, $117,144 in expense of which had yet to be taken at the time of cancellation were cancelled pursuant to the terms of such warrants dictating cancellation upon the two-month anniversary of a cease of service; and ii) warrants for13,500 shares that were never originally valued, were to be vested upon billing from service providers, and were cancelled due to termination of these relationships. A summary of warrant activity for the year ending March 31, 2020 and nine-month period ending December 31, 2020 is as follows: Number of Weighted- Warrants Weighted- Outstanding, March 31, 2019 954,745 2.20 758,759 2.16 Granted 476,425 2.07 Cashless warrant exercises (84,375 ) 1.27 Expired (22,500 ) 2.22 Canceled (99,000 ) 2.32 Outstanding, March 31, 2020 1,225,295 2.12 1,018,092 2.13 Issued in conjunction with convertible debt 158,036 1.40 Sold for cash 10,000 4.00 Issued and granted 72,596 1.52 Exercised for cash (202,499 ) 2.22 Cashless warrant exercises (116,125 ) 1.49 Expired (22,500 ) 7.56 Outstanding, December 31, 2020 1,124,803 1.99 1,100,306 1.87 At December 31, 2020, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price 1.20-2.00 696,190 1.36 4.61 850,568 1.34 2.01-4.00 320,438 2.39 3.67 134,813 2.62 4.01-10.00 108,175 4.94 1.75 114,925 4.91 Total 1,124,803 1.99 4.07 1,100,306 1.87 For the nine-month periods ended December 31, 2020 and 2019, the total stock-based compensation on all instruments was $889,597 and $791,256, respectively. It is expected that the Company will recognize expense after December 31, 2020 related to warrants issued, outstanding, and valued using the Black Scholes pricing model as of December 31, 2020 in the amount of approximately $287,000.

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 14 – SUBSEQUENT EVENTS On January 4, 2021, the Company issued John Lai 38,516 shares pursuant to his cashless exercise of 42,188 warrants with a strike price of $1.33 per share. On January 15, 2021, the Company received a conversion notice from one of its convertible note holders whereby they converted $50,000 in convertible note principal and $205 in accrued interest into 17,379 shares of common stock at a conversion rate of $2.89/share. On January 29, 2021, one warrant holder exercised their warrant for 17,188 shares with a strike price of $1.20 per share on a cashless basis and received 15,629 shares pursuant to the same. On February 9, 2021, one warrant holder exercised their warrant for 9,000 shares with a strike price of $4.44 per share on a cashless basis and received 5,163 shares pursuant to the same.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Organization (Policies)	9 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description	(A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota.
Basis of Presentation	(B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. In October 2020, the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was made effective December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000; all share and per share data has been retroactively adjusted for this reverse split for all period presented. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. Although these interim financial statements at December 31, 2020 and for the nine months ended December 31, 2020 and 2019 are unaudited, in the opinion of our management, such statements include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the nine months ended December 31, 2020 are not necessarily indicative of the results to be expected for the year ended March 31, 2021 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2020, included in our annual report on Form 10-K filed with the SEC on June 29, 2020.
Principles of Consolidation	(C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation.
Use of Estimates	(D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include collectability of accounts receivable, estimated useful lives and potential impairment of property and equipment and intangible assets, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, estimate of fair value of lease liabilities and related right of use asset, valuation of deferred tax assets and valuation of in-kind contribution of services and interest.
Cash and Cash Equivalents	(E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2020, the Company had $230,969 in cash and no cash equivalents. At March 31, 2020, the Company had $10,582 in cash and restricted cash and no cash equivalents.
Concentration-Risk	(F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed limits insured by the Federal Deposit Insurance Corporation (FDIC). At December 31, 2020, cash did not exceed the FDIC uninsured balances and management believes the Company is not exposed to any significant credit risk on cash.
Property & Equipment	(G) Property & Equipment Property and equipment are recorded at cost less accumulated depreciation. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after taking into account their respective estimated residual values) over the asset’s estimated useful life of (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures.
Patents and Trademarks	(H) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60 months or the life of the patent. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired.
Loss Per Share	(I) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 1,124,803 warrants outstanding as of December 31, 2020 with varying exercise prices ranging from $1.20 to $15.56/share. The weighted average exercise price for these warrants is $1.99/share. These warrants are excluded from the weighted average number of shares because they are considered anti-dilutive. The Company had 1,305,111 warrants outstanding as of December 31, 2019, with varying exercise prices ranging from $1.20 to $15.56/share. The weighted average exercise price for these warrants was $2.16/share. These warrants are excluded from the weighted average number of shares because they are considered antidilutive. The Company uses the guidance in ASC 260 to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive. At December 31, 2020, the Company had $280,000 in convertible notes principal and $-0- in interest outstanding; at December 31, 2019, the Company had $280,000 in convertible notes principal and $7,057 in interest outstanding; these notes mature in our fiscal quarter ended June 30, 2021. If converted, the $280,000 in outstanding principal and $-0- in accrued interest would convert into 96,924 shares of common stock at a rate of $2.89 per share. Also at December 31, 2020, the Company had a share-settled debt obligation with a related party wherein $196,000 in principal will be converted into units of one share of common stock and one warrant for a share of common stock with the exact number of units to be determined by the terms of an S-1 offering that as of this filing has yet to take place. See Note 8 to these financial statements for more information on the convertible notes discussed in this paragraph.
Revenue Recognition	(J) Revenue Recognition The Company recognizes revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers.” Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company adopted the guidance on April 1, 2018 using the cumulative catch-up transition method. This change in accounting did not have any material effect on the Company’s financial statements. The Company recognizes revenue related to our sales of Kush product to veterinarians when the performance obligation is met, which is when we have received an order and shipped the Kush product.
Research and Development	(K) Research and Development The Company expenses research and development costs as incurred.
Fair Value of Financial Instruments	(L) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements,” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of investments – equity securities receivable, notes payable and accrued interest, notes payable and accrued interest - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2020 and March 31, 2020, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company measured its investments – equity securities receivable at fair value at December 31, 2020, and March 31, 2020, see Note 4 to the financial statements included in this Form 10-Q. The Company accounts for derivative instruments in accordance with Accounting Standards Codification 815, Derivatives and Hedging (“ASC 815”), which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities. ASC 815 requires that an entity recognize all derivatives as either assets or liabilities in the balance sheet and measure those instruments at fair value, which are in level 3 of the fair value hierarchy. If certain conditions are met, a derivative may be specifically designated as a hedge, the objective of which is to match the timing of gain or loss recognition on the hedging derivative with the recognition of (i) the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk or (ii) the earnings effect of the hedged forecasted transaction. For a derivative not designated as a hedging instrument, the gain or loss is recognized in income in the period of change.
Stock-Based Compensation - Employees and Non-Employees	(M) Stock-Based Compensation – Employees and Non-Employees Equity Instruments Issued to Employees and Non-Employees for Acquiring Goods or Services On June 20, 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (for example, service providers, external legal counsel, suppliers, etc.). Under the new standard, companies will no longer be required to value non-employee awards differently from employee awards. Meaning that companies will value all equity classified awards at their grant-date under ASC 718 and forgo revaluing the award after this date. The Company accounts for employee stock-based compensation the same as non-employee stock-based compensation. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments.
Income Taxes	(N) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. As required by ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied ASC Topic 740 to all tax positions for which the statute of limitations remained open. As a result of the implementation of ASC Topic 740, the Company did not recognize any change in the liability for unrecognized tax benefits. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses.
Inventory	(O) Inventory Inventories are recorded in accordance with ASC 330 and are stated at the lower of cost and net realizable value. We account for inventories using the first in first out (FIFO) methodology and capitalize costs on a project basis as they occur. The current marketed shelf life of our Kush inventory is 3 years. However, management reserves the right to review and adjust this as appropriate.
Recently Issued and Adopted Accounting Pronouncements	( P) Recently Issued and Adopted Accounting Pronouncements In January 2017, the FASB issued ASU No. 2017-04, “Intangibles and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates the requirement to calculate the implied fair value of goodwill, but rather requires an entity to record an impairment charge based on the excess of a reporting unit’s carrying value over its fair value. This amendment is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We adopted this ASU on April 1, 2020 and it did not have a material effect on our consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements on fair value measurements in Topic 820. The ASU is effective for the Registrants for fiscal years beginning after December 15, 2019, and interim periods therein. The Company adopted this ASU on April 1, 2020 and it did not have a material impact on the financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Lease and Commitments (Tables)

Lease and Commitments (Tables)	9 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Maturity Analysis of Operating Lease Liabilities	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of December 31, 2020: Year Ended March 31, 2021 $ 6,614 2022 26,634 2023 27,167 2024 27,710 2025 28,265 Thereafter 48,305 $ 164,695 Less: Amount representing interest (345 ) Present value of lease liabilities $ 164,350
Schedule of Future Lease Payments	December 31, 2020 Present value of future base rent lease payments $ 164,350 Base rent payments included in prepaid expenses - Present value of future base rent lease payments – net $ 164,350
Schedule of Present Value of Future Lease Payments Between Current and Non-current Assets and Liabilities	As of December 31, 2020, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: December 31, 2020 Operating lease right-of-use asset $ 164,350 Total operating lease assets 164,350 Operating lease current liability 26,450 Operating lease other liability 137,900 Total operating lease liabilities $ 164,350

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Dec. 31, 2020
Property and Equipment:
Schedule of Property and Equipment	The components of property and equipment were as follows: December 31, 2020 March 31, 2020 Leasehold improvements $ 177,184 $ 98,706 Furniture and office equipment 10,130 10,130 Production equipment 127,419 87,473 R&D equipment 25,184 25,184 Total, at cost 339,917 221,493 Accumulated depreciation (136,318 ) (111,586 ) Total, net $ 203,599 $ 109,907

Trademarks and Patents, Net (Ta

Trademarks and Patents, Net (Tables)	9 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The components of intangible assets, all of which are finite-lived, were as follows: December 31, 2020 March 31, 2020 Patents $ 3,836,911 $ 3,822,542 Trademarks 26,142 25,023 Total, at cost 3,863,053 3,847,565 Accumulated Amortization (3,837,284 ) (3,788,954 ) Total, net $ 25,769 $ 58,611

Notes Payable and Convertible_2

Notes Payable and Convertible Notes (Tables)	9 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable and Accrued Interest	At March 31, 2020, the Company is obligated for $76,350 in notes payable and accrued interest and $286,981 in convertible notes payable and accrued interest. December 31, 2020 March 31, 2020 Notes Payable Convertible Notes Payable Notes Payable Convertible Notes Payable 1. Third Parties – Principal $ 79,634 $ 280,000 $ 15,000 $ 280,000 Third Parties – Interest 260 - 95 6,981 Third Parties – Total 79,894 280,000 15,095 286,981 2. Related Parties – Principal 49,826 - 59,642 - Related Parties – Interest - - 1,613 - Related Parties – Total 49,826 - 61,255 - Total $ 129,720 $ 280,000 $ 76,350 $ 286,981

Derivative Liability and Expe_2

Derivative Liability and Expense (Tables)	9 Months Ended
	Dec. 31, 2020
Derivative Liability [Abstract]
Schedule of Derivative Liability Assumptions	The Company used the following assumptions for determining the fair value of the conversion feature in the RDCN referenced in Note 8 to these consolidated financial statements, under the binomial pricing model at June 15, 2020, September 30, 2020, and October 26, 2020, the issuance, balance sheet, and conversion dates, respectively: June 15, 2020 September 30, 2020 October 26, 2020 Stock price on valuation date $ 1.68 $ 1.60 $ 6.56 Conversion price $ 1.12 $ 1.12 $ 1.12 Days to maturity 273 166 140 Weighted-average volatility* 367 % 327 % 197 % Risk-free rate .18 % .12 % .11 %
Schedule of Derivative Liability	The Company recorded derivative liability transactions during the nine-month period ended December 31, 2020 as follows: Nine Months Ended December 31, 2020 Convertible note embedded derivative liability Balance at March 31, 2020 $ -0- Initial recognition of derivative liability 526,800 Change in fair value 21,400 Balance at June 30, 2020 $ 548,200 Change in fair value 389,300 Balance at September 30, 2020 $ 937,500 Change in fair value 970,600 Balance at October 26, 2020 $ 1,908,100 Conversion of note on October 26,2020 (1,908,100 ) Balance at December 31, 2020 $ -0-

Common Stock and Warrants (Tabl

Common Stock and Warrants (Tables)	9 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Schedule of Warrant Activity	A summary of warrant activity for the year ending March 31, 2020 and nine-month period ending December 31, 2020 is as follows: Number of Weighted- Warrants Weighted- Outstanding, March 31, 2019 954,745 2.20 758,759 2.16 Granted 476,425 2.07 Cashless warrant exercises (84,375 ) 1.27 Expired (22,500 ) 2.22 Canceled (99,000 ) 2.32 Outstanding, March 31, 2020 1,225,295 2.12 1,018,092 2.13 Issued in conjunction with convertible debt 158,036 1.40 Sold for cash 10,000 4.00 Issued and granted 72,596 1.52 Exercised for cash (202,499 ) 2.22 Cashless warrant exercises (116,125 ) 1.49 Expired (22,500 ) 7.56 Outstanding, December 31, 2020 1,124,803 1.99 1,100,306 1.87
Schedule of Range of Warrant Prices	At December 31, 2020, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price 1.20-2.00 696,190 1.36 4.61 850,568 1.34 2.01-4.00 320,438 2.39 3.67 134,813 2.62 4.01-10.00 108,175 4.94 1.75 114,925 4.91 Total 1,124,803 1.99 4.07 1,100,306 1.87

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Organization (Details Narrative) - USD ($)	Dec. 29, 2020	Oct. 23, 2020	Oct. 31, 2020	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Reverse stock split, description	On December 29, 2020, the Company effected a reverse stock split of all its outstanding common stock at a ratio of 1-for-4 shares. Pursuant to this reverse stock split, each four (4) shares of PetVivo's outstanding common stock, $.001 par value per share, was combined and converted into one (1) post-split outstanding shares of common stock, $.001 par value per share. This reverse stock split affected all PetVivo shareholders uniformly and accordingly did not alter any shareholder's percentage interest or ownership of PetVivo equity. Through the date of this filing, 724 shares of common stock have been issued due to rounding up of fractional shares.	The Company approved and declared a reverse stock split of all its outstanding common stock at a ratio of 1-for-4 shares; this reverse stock split was made effective on December 29, 2020.	Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was made effective December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000; all share and per share data has been retroactively adjusted for this reverse split for all period presented.	1-for-4 reverse split
Common stock, shares authorized	225,000,000			250,000,000	250,000,000		250,000,000
Increased in authorized shares of common stock due to adjusted for reverse split					250,000,000
Cash				$ 230,969	$ 230,969		$ 10,582
Cash equivalents
Restricted cash							10,582
Debt instrument maturity date					Apr. 30, 2020
Share-settled debt obligation with a related party					$ 196,000
Accrued interest							6,981
Assets and liabilities measured at fair value
Income tax likelihood percentage					Greater than 50 percent
Inventory terms					3 years
Convertible Notes [Member]
Convertible notes outstanding				280,000	$ 280,000	280,000
Convertible notes interest outstanding				$ 0	$ 0	$ 7,057
Debt instrument maturity date					Jun. 30, 2021
Conversion of debt into common stock amount					$ 280,000
Conversion of debt into common stock shares					96,924
Conversion price per share				$ 2.89	$ 2.89
Warrant [Member]
Warrants outstanding					1,124,803	1,305,111
Weighted average, exercise price					$ 1.99	$ 2.16
Warrant [Member] | Minimum [Member]
Warrant exercise price				1.20	1.20	15.56
Warrant [Member] | Maximum [Member]
Warrant exercise price				$ 15.56	$ 15.56	$ 1.20
Patents and Trademarks [Member]
Estimated useful life of intangible asset					60 months
Equipment [Member]
Estimated useful life of assets					3 years
Automobile [Member]
Estimated useful life of assets					5 years
Furniture and Fixtures [Member]
Estimated useful life of assets					7 years

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (1,037,753)	$ (1,348,002)	$ (814,008)	$ (551,193)	$ (519,173)	$ (500,887)	$ (3,199,763)	$ (1,571,252)
Net cash used in operating activities							(776,845)	(415,138)
Accumulated deficit	(57,788,408)						(57,788,408)		$ (54,588,645)
Working capital	(821,219)						(821,219)
Stockholders' deficit	$ (661,956)	$ (1,927,691)	$ (1,575,434)	$ (748,110)	$ (799,095)	$ (1,154,903)	$ (661,956)	$ (748,110)	$ (1,036,170)	$ (844,817)

Lease and Commitments (Details

Lease and Commitments (Details Narrative)	May 03, 2017USD ($)ft²	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Mar. 31, 2020USD ($)	Jan. 08, 2020USD ($)
Rent expense		$ 13,343	$ 13,434	$ 40,479	$ 37,679
Area of land | ft²	3,577
Base rent	$ 2,078	2,162		$ 2,162
Annual increase in rent	0.02
Unusable period	45 days
Lease term description				Company entered into a lease amendment whereby agreed to extend the lease term through November of 2026
Operating lease, right-use of asset		164,350		$ 164,350		$ 148,693	$ 189,600
Operating lease payment		$ 164,695		$ 164,695
Operating lease discount rate		0.12%		0.12%
Weighted average remaining lease term		6 years		6 years
Weighted average discount rate		0.12%		0.12%
Gel-Del Technologies, Inc [Member]
Operating lease payment		$ 330,000		$ 330,000

Lease and Commitments - Schedul

Lease and Commitments - Schedule of Maturity Analysis of Operating Lease Liabilities (Details)	Dec. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 6,614
2022	26,634
2023	27,167
2024	27,710
2025	28,265
Thereafter	48,305
Total	164,695
Less: Amount representing interest	(345)
Present value of lease liabilities	$ 164,350

Lease and Commitments - Sched_2

Lease and Commitments - Schedule of Future Lease Payments (Details)	Dec. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
Present value of future base rent lease payments	$ 164,350
Base rent payments included in prepaid expenses
Present value of future base rent lease payments - net	$ 164,350

Lease and Commitments - Sched_3

Lease and Commitments - Schedule of Present Value of Future Lease Payments Between Current and Non-current Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Mar. 31, 2020	Jan. 08, 2020
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use asset	$ 164,350
Total operating lease assets	164,350	$ 148,693	$ 189,600
Operating lease current liability	26,450	24,791
Operating lease other liability	137,900	$ 123,901
Total operating lease liabilities	$ 164,350

Investments - Equity Securiti_2

Investments - Equity Securities (Details Narrative) - USD ($)	Jun. 28, 2020	Dec. 31, 2020
Fair value of investments		$ 1,500
Purchase Agreement [Member] | Emerald Organic Products Inc [Member]
Number of shares purchased for acquisition	1,500,000
Value of shares purchased for acquisition	$ 1,500

Prepaid Expenses and Deferred_2

Prepaid Expenses and Deferred Offering Costs (Details Narrative) - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Prepaid expenses and deferred offering costs	$ 252,431	$ 132,023
Prepaid expenses - short term	141,687	132,023
Deferred offering costs	110,744
Advertising and Marketing Services [Member]
Prepaid expenses - short term	73,000
Deposit for Canine Elbow Osteoarthritis Study [Member]
Prepaid expenses - short term	$ 25,000

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Property and Equipment:
Depreciation expense	$ 10,768	$ 2,438	$ 24,731	$ 12,861
Proceeds from sale of equipment			$ 482	450
Gain on sale of piece of equipment				450
Original purchase price of an equipment				$ 1,004

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Total, at cost	$ 339,917	$ 221,493
Accumulated depreciation	(136,318)	(111,586)
Total, net	203,599	109,907
Leasehold Improvements [Member]
Total, at cost	177,184	98,706
Furniture and Office Equipment [Member]
Total, at cost	10,130	10,130
Production Equipment [Member]
Total, at cost	127,419	87,473
R&D Equipment [Member]
Total, at cost	$ 25,184	$ 25,184

Trademarks and Patents, Net (De

Trademarks and Patents, Net (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 1,629	$ 134,283	$ 48,331	$ 408,994
Intangible impairment expense	$ 8,353	$ 28,038	$ 23,930	$ 28,038

Trademarks and Patents, Net - S

Trademarks and Patents, Net - Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 3,836,911	$ 3,822,542
Trademarks	26,142	25,023
Total, at cost	3,863,053	3,847,565
Accumulated Amortization	(3,837,284)	(3,788,954)
Total, net	$ 25,769	$ 58,611

Notes Payable and Convertible_3

Notes Payable and Convertible Notes (Details Narrative) - USD ($)	Oct. 26, 2020	Oct. 26, 2020	Aug. 14, 2020	May 02, 2020	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Oct. 30, 2020	Jun. 30, 2020	May 14, 2020	Mar. 31, 2020	Jan. 08, 2020
Notes payable					$ 129,720				$ 129,720	$ 129,720					$ 76,350	$ 42,500
Convertible Notes payable					280,000				280,000	$ 280,000					286,981
Convertible notes maturity date										Apr. 30, 2020
Accrued interest															6,981
Convertible notes accrued interest rate																6.00%
Discount on debt					1,421				1,421
Unamortized Debt Discount					(1,421)				(1,421)	$ (1,421)
Interest expenses					35,919					173,174
Derivative liability	$ 1,908,100	$ 1,908,100			0	$ 937,500			0	0			$ 548,200		0
Debt conversion stock valued										1,729,005
Gain on debt extinguishment					(366,903)					$ (366,903)	81,738
Value of common stock issued					1,729,005	$ 25,382		$ 537,703
Conversion price per share description										These AICNs automatically convert into shares of common stock at a rate of $2.89 per share at the earlier of the maturity date or an uplist to a national securities exchange (e.g. NASDAQ or New York Stock Exchange) provided that the Company's stock price is at least $3.47 at the time of the uplist. The AICN note holders have the right to convert their outstanding principal and interest into shares of the Company's common stock at any time during their note's term at $2.89 per share.
Notes payable, current					40,969				40,969	$ 40,969					15,000
Accrued interest, current					0				0	0					95
Accrued interest paid					559					45,850	16,338
Repayments of notes payable					1,531					4,190	18,831
Proceeds from PPP note payable										38,665
Note payable and accrued interest - related party					49,826				49,826	49,826					61,255
Three Directors [Member]
Conversion price per share			$ 1.02
Accrued interest			$ 382
Debt Principal			$ 25,000
Note Conversion Agreement [Member]
Convertible Notes payable	$ 368,995	$ 368,995
Conversion price per share	$ 1.40	$ 1.40
Accrued interest	$ 16,054	$ 16,054
Debt Principal	352,941	352,941
Unamortized Debt Discount	$ (181,187)	$ (181,187)
Stock price	$ 6.56	$ 6.56
Derivative liability	$ 1,908,100	$ 1,908,100
Debt principal and accrued interest	368,995	$ 368,995
Debt conversion stock valued	1,729,005
Gain on debt extinguishment	$ 366,903
Shares of common stock issued	263,568
Paycheck Protection Program [Member]
Convertible notes maturity date				May 1, 2022
Convertible notes accrued interest rate				1.00%
Debt Principal				$ 38,665
Accrued interest, current				260
Proceeds from PPP note payable				38,665
Outstanding balance				$ 38,925
15% OID Convertible Note [Member]
Discount on debt										(52,941)
Total Debt issuance cost										61,500
Convertible Note Payable [Member] | Three Directors [Member]
Conversion price per share			$ 1.02
Accrued interest			$ 382
Convertible notes accrued interest rate														6.00%
Debt Principal														$ 25,000
Outstanding balance			$ 25,382
Shares of common stock issued			25,003
Value of common stock issued			$ 25,383
Convertible Note Payable [Member] | Paid-Out Accrued Interest [Member]
Payment of convertible debt					14,115		$ 0			28,077	$ 11,479
Convertible Note Payable [Member] | Derivative [Member]
Discount on debt										(206,000)
Convertible Note Payable [Member] | Investor [Member]
Discount on debt										(2,500)
Convertible Note Payable [Member] | Think Equity [Member]
Discount on debt										(52,399)
Payment of convertible debt										$ 31,500
Convertible Note Payable [Member] | Think Warrants [Member]
Number of Warrants issued										75,000
Accredited Investor Convertible Notes [Member]
Convertible Notes payable					280,000				280,000	$ 280,000					286,981
Accrued interest					0				0	0					6,981
Debt Principal					280,000				280,000	280,000					$ 280,000
Amended Promissory Note [Member]
Accrued interest					0				0	0
Debt Principal					49,826				49,826	49,826
RedDiamond Partners, LLC [Member]
Convertible Notes payable					$ 352,941				$ 352,941	$ 352,941
Convertible notes maturity date										Mar. 15, 2021
Conversion price per share	$ 1.40	$ 1.40			$ 1.12				$ 1.12	$ 1.12
Accrued interest					$ 52,941				$ 52,941	$ 52,941
Original issue discount percentage					15.00%				15.00%	15.00%
Convertible notes accrued interest rate					12.50%				12.50%	12.50%
Number of warrants purchase					139,286				139,286	139,286
Warrants purchase Amount					$ 91,500				$ 91,500	$ 91,500
Debt Principal					352,941				352,941	352,941
Discount on debt										(91,500)
Payment of convertible debt										30,000
Unamortized Debt Discount					0				0	0
Owed amount					$ 0				$ 0	$ 0
Debt principal and accrued interest												$ 368,995
Gain on debt extinguishment		$ 366,903
Shares of common stock issued		263,568

Notes Payable and Convertible_4

Notes Payable and Convertible Notes - Schedule of Convertible Notes Payable and Accrued Interest (Details) - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Interest		$ 6,981
Notes Payable [Member]
Total	$ 129,720	76,350
Notes Payable [Member] | Related Party [Member]
Debt Principal	49,826	59,642
Interest		1,613
Total	49,826	61,255
Notes Payable [Member] | Third parties [Member]
Debt Principal	79,634	15,000
Interest	260	95
Total	79,894	15,095
Convertible Note Payable [Member]
Total	280,000	286,981
Convertible Note Payable [Member] | Related Party [Member]
Debt Principal
Interest
Total
Convertible Note Payable [Member] | Third parties [Member]
Debt Principal	280,000	280,000
Interest		6,981
Total	$ 280,000	$ 286,981

Share-settled Debt Obligation_2

Share-settled Debt Obligation - Related Party (Detail Narrative) - USD ($)	Oct. 15, 2020	Sep. 02, 2020	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2020	Mar. 31, 2020	Jan. 08, 2020
Share-settled debt obligation - related party			$ 194,579	$ 194,579	$ 194,579
Unamortized discount on debt			(1,421)	(1,421)	(1,421)
Discount on debt			1,421	1,421
Accrued Interest						6,981
Notes payable			129,720	129,720	$ 129,720	$ 76,350	$ 42,500
Debt interest rate							6.00%
Debt instrument maturity date					Apr. 30, 2020
Amended Promissory Note [Member]
Notes payable principle Amount			49,826	49,826	$ 49,826
Accrued Interest			0	0	0
Amended Promissory Note [Member] | David B Masters [Member]
Notes payable principle Amount		$ 59,642
Additional term		2 years
Accrued Interest		$ 6,058
Notes payable		$ 65,700	195,000	195,000	195,000
Debt interest rate		8.00%
Debt default interest rate		20.00%
Debt instrument maturity date		Jun. 30, 2022
Annual monthly payments		$ 3,100
Debt instrument convenient gross proceeds from product sale		1,500,000
Debt instrument convenient proceeds from equity sales		1,500,000
Promissory Note [Member]
Notes payable principle Amount			0	0	0
Accrued Interest			0	0	0
Promissory Note [Member] | David B Masters [Member]
Notes payable principle Amount	$ 192,500	$ 195,000
Accrued Interest	658
Debt interest rate		3.00%
Debt instrument maturity date		Aug. 31, 2022
Annual monthly payments		$ 4,000
Debt instrument convenient gross proceeds from product sale		3,500,000
Debt modification		$ 195,000
Debt principal and accrued interest	193,158
Debt conversion amount	196,000
Conversion fee	$ 3,500
Maximum [Member]
Notes payable principle Amount			$ 196,000	$ 196,000	$ 196,000

Derivative Liability and Expe_3

Derivative Liability and Expense (Details Narrative) - USD ($)	Oct. 26, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Jun. 15, 2020	Mar. 31, 2020
Recognition of derivative liability								$ 526,800
Discount on debt								206,000
Convertible note embeded derivative liability								$ 0
Derivative expense				320,800
Corresponding offset to derivative liability		526,800		526,800
Derivative liability	$ 1,908,100	0		0		$ 937,500	$ 548,200		$ 0
Derivative Expense		970,600		1,702,100
Gain on debt extinguishment		$ (366,903)		$ (366,903)	$ 81,738
RedDiamond Partners, LLC [Member]
Shares of common stock issued	263,568
Conversion price per share	$ 1.40	$ 1.12		$ 1.12
Gain on debt extinguishment	$ 366,903

Derivative Liability and Expe_4

Derivative Liability and Expense - Schedule of Derivative Liability Assumptions (Details)	Oct. 26, 2020$ / shares	Jun. 15, 2020$ / shares	Sep. 30, 2020$ / shares
Stock price on valuation date	$ 6.56	$ 1.68	$ 1.60
Conversion price	$ 1.12	$ 1.12	$ 1.12
Days to maturity	140 days	273 days	166 days
Weighted-average Volatility [Member]
Derivative liability measurement input, percentage	197	367	327
Risk-free Rate [Member]
Derivative liability measurement input, percentage	0.11	.18	0.12

Derivative Liability and Expe_5

Derivative Liability and Expense - Schedule of Derivative Liability (Details) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended
	Oct. 26, 2020	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020
Derivative Liability [Abstract]
Beginning balance	$ 937,500	$ 1,908,100	$ 548,200	$ 0
Initial recognition of derivative liability				526,800
Change in fair value	970,600		389,300	21,400
Conversion of note		(1,908,100)
Ending balance	$ 1,908,100	$ 0	$ 937,500	$ 548,200

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Details Narrative) - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 782,732	$ 794,057
Accounts payable	555,960	556,653
Accrued salaries and payroll taxes	226,722	237,404
Accrued liability for the potential taxes	$ 14,198	$ 22,025

Accrued Expenses - Related Pa_2

Accrued Expenses - Related Party (Details Narrative) - USD ($)	Dec. 31, 2020	Sep. 02, 2020	Mar. 31, 2020	Jan. 08, 2020
Notes payable	$ 129,720		$ 76,350	$ 42,500
Accounts payable	555,960		556,653
Accrued salaries and payroll taxes payable	226,722		237,404
Amended Promissory Note [Member] | David B Masters [Member]
Notes payable	195,000	$ 65,700
Claim on past accrued salary	195,000
Related Party [Member]
Accrued expenses, related party	9,615		252,607
Accounts payable			38,954
Accrued salaries and payroll taxes payable			$ 213,653
Related Party [Member] | John Lai and John Carruth [Member]
Accrued expenses, related party	$ 4,807

Common Stock and Warrants (Deta

Common Stock and Warrants (Details Narrative)	Dec. 29, 2020	Oct. 31, 2020$ / sharesshares	Oct. 30, 2020USD ($)$ / sharesshares	Oct. 26, 2020USD ($)$ / shares	Oct. 23, 2020	Sep. 14, 2020USD ($)shares	Aug. 14, 2020USD ($)$ / sharesshares	Jul. 24, 2020USD ($)$ / sharesshares	Jul. 10, 2020shares	Jul. 02, 2020USD ($)shares	Jun. 15, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 09, 2019USD ($)$ / sharesshares	Sep. 18, 2019USD ($)shares	Sep. 13, 2019USD ($)shares	Jul. 13, 2019USD ($)shares	Dec. 31, 2020USD ($)$ / sharesshares	Oct. 31, 2020$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Apr. 30, 2020shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2020USD ($)$ / sharesshares
Reverse stock split, description	On December 29, 2020, the Company effected a reverse stock split of all its outstanding common stock at a ratio of 1-for-4 shares. Pursuant to this reverse stock split, each four (4) shares of PetVivo's outstanding common stock, $.001 par value per share, was combined and converted into one (1) post-split outstanding shares of common stock, $.001 par value per share. This reverse stock split affected all PetVivo shareholders uniformly and accordingly did not alter any shareholder's percentage interest or ownership of PetVivo equity. Through the date of this filing, 724 shares of common stock have been issued due to rounding up of fractional shares.				The Company approved and declared a reverse stock split of all its outstanding common stock at a ratio of 1-for-4 shares; this reverse stock split was made effective on December 29, 2020.													Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was made effective December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000; all share and per share data has been retroactively adjusted for this reverse split for all period presented.	1-for-4 reverse split
Number of shares issued																														991,014	652,466
Value of shares issued | $
Number of shares issued for compensation
Value of shares issued for compensation | $																				$ 653,863	$ 183,244		363,178	$ 237,278	$ 190,801					$ 889,597
Accrued interest | $																						$ 6,981										$ 6,981
Shares issued description																														20,000 shares with a relative value of $34,709 pursuant to a purchase of 20,000 units whereby a unit is made up of 1 share of common stock and ½ warrant. The value of $34,709 along with the relative value of the warrants associated with this transaction of $17,291 ($52,000 total) was recorded during the quarter ended March 31, 2020 to Common Stock Subscribed and moved to Additional Paid in Capital and Capital Stock upon receipt of funds and issuance of shares of common stock during the quarter ended June 30, 2020;
Fair value of warrants | $																														$ 91,500
Number of shares issued for services														67,500		27,000
Number of shares issued for services, value | $														$ 102,000		$ 120,000
Loss on extinguishment of debt | $																			$ 366,903											366,903	$ (81,738)
Warrant expense recognized | $																														287,000
Stock-based compensation | $																														$ 889,597	$ 791,256
Minimum [Member] | Expected Volatility [Member]
Warrant measurement inputs												313					350		350				313				350	313		350	313
Minimum [Member] | Risk-Free Interest [Member]
Warrant measurement inputs												2.30					0.29		0.29				2.30				0.29	2.30		0.29	2.30
Maximum [Member]
Debt Principal | $																	$ 196,000		$ 196,000								$ 196,000			$ 196,000
Maximum [Member] | Expected Volatility [Member]
Warrant measurement inputs												361					433		433				361				433	361		433	361
Maximum [Member] | Risk-Free Interest [Member]
Warrant measurement inputs												1.51					1.16		1.16				1.51				1.16	1.51		1.16	1.51
Warrants [Member]
Warrants to purchase shares of common stock												81,000											81,000					81,000			81,000
Warrant granted to purchase shares of common stock																														240,632	433,633
Warrant granted to purchase shares of common stock, value | $																														$ 443,098	$ 914,730
Cancellation of warrants to purchase common stock																															81,000
Warrant [Member]
Warrants to purchase shares of common stock												67,500											67,500					67,500			67,500
Warrant to purchase of common stock, value | $												$ 300,770											$ 300,770					$ 300,770			$ 300,770
Warrant granted to purchase shares of common stock																																476,425
Warrant expense recognized | $																													$ 117,144
Warrant [Member] | Minimum [Member]
Warrants exercise price | $ / shares												$ 15.56					$ 1.20		$ 1.20				$ 15.56				$ 1.20	$ 15.56		$ 1.20	$ 15.56
Warrant [Member] | Maximum [Member]
Warrants exercise price | $ / shares												$ 1.20					$ 15.56		$ 15.56				$ 1.20				$ 15.56	$ 1.20		$ 15.56	$ 1.20
Warrant One [Member]
Cancellation of warrants to purchase common stock																															13,500
Accrued Expenses - Related Party [Member]
Reduction in accrued compensation | $																															$ 375,936
Accounts Payable and Accrued Expenses [Member]
Reduction in accrued compensation | $																															$ 80,029
20 Accredited Investor [Member]
Warrants to purchase shares of common stock																	202,499		202,499								202,499			202,499
Warrants exercise price | $ / shares																	$ 2.22		$ 2.22								$ 2.22			$ 2.22
Warrant granted to purchase shares of common stock, value | $																														$ 449,993
Warrant Holder's [Member]
Warrants to purchase shares of common stock		6,750																6,750
Warrants exercise price | $ / shares		$ 4.44																$ 4.44
Warrant granted to purchase shares of common stock																		793
Accredited Investors [Member]
Number of shares issued for services																											121,500
Number of shares issued for services, value | $																											$ 135,000
Investor [Member]
Number of shares issued for services																										22,500
Investor and Broker [Member]
Warrants to purchase shares of common stock											158,036
Warrant to purchase of common stock, value | $											$ 265,500
Value of warrant vested | $											$ 91,500
Warrants exercise price | $ / shares											$ 1.40
Warrants exercise term											5 years
RedDiamond Partners, LLC [Member]
Warrants to purchase shares of common stock																	139,286		139,286								139,286			139,286
Debt Principal | $																	$ 352,941		$ 352,941								$ 352,941			$ 352,941
Debt principal and accrued interest | $			$ 368,995
Accrued interest | $																	$ 52,941		$ 52,941								$ 52,941			$ 52,941
Conversion price | $ / shares				$ 1.40													$ 1.12		$ 1.12								$ 1.12			$ 1.12
Number of shares issued for conversion			263,568
Number of shares issued for conversion, value | $			$ 1,729,005
Loss on extinguishment of debt | $				$ (366,903)
Launchpad IR [Member]
Number of shares issued for services													37,500
Number of shares issued for services, value | $													$ 70,500
Share price per share | $ / shares													$ 1.68
One Share of Common Stock and 1/2 Warrant Share [Member]
Warrants to purchase shares of common stock												40,000										20,000	40,000					40,000			40,000	20,000
Warrant to purchase of common stock, value | $												$ 104,000										$ 34,709	$ 104,000					$ 104,000			$ 104,000	$ 34,709
Fair value of warrants | $												$ 69,391										34,709
Warrant transaction cost | $																						$ 17,291
Warrants exercise price | $ / shares												$ 2.60											$ 2.60					$ 2.60			$ 2.60
Video Marketing Services [Member]
Number of shares issued for compensation																														30,000
Value of shares issued for compensation | $																														$ 40,680
Two Service Provider [Member]
Number of shares issued for services										12,500
Number of shares issued for services, value | $										$ 22,000
Marketing and Investor Relations Service Provider [Member]
Number of shares issued for services										10,000
Number of shares issued for services, value | $										$ 17,600
Legal Service Provider [Member]
Number of shares issued for services										2,500
Number of shares issued for services, value | $										$ 4,400
One Warrant Holder [Member]
Number of shares issued								15,257
Value of shares issued | $								$ 12,053
Warrants converted on cashless basis								25,000
Warrants exercise price | $ / shares								$ 1.20
Four Accredited Investors [Member]
Number of shares issued																	226,071
Value of shares issued | $																	$ 316,500
Directors and Officers [Member]
Number of shares issued for compensation						162,252
Value of shares issued for compensation | $						$ 486,755
Directors and Officers [Member] | Warrants [Member]
Warrants to purchase shares of common stock												413,633											413,633					413,633			413,633
Warrant to purchase of common stock, value | $												$ 880,121											$ 880,121					$ 880,121			$ 880,121
Warrants exercise term												5 years											5 years					5 years			5 years
Directors and Officers [Member] | Warrants [Member] | Minimum [Member]
Warrants exercise price | $ / shares												$ 1.33											$ 1.33					$ 1.33			$ 1.33
Directors and Officers [Member] | Warrants [Member] | Maximum [Member]
Warrants exercise price | $ / shares												$ 2.22											$ 2.22					$ 2.22			$ 2.22
John Lai [Member]
Number of shares issued			42,188
Number of shares issued for compensation						33,619
Warrants exercise price | $ / shares			$ 1.33
Warrant granted to purchase shares of common stock			32,347
Number of escrowed shares		150,000
John Lai [Member] | Settlement Agreement [Member]
Number of shares issued for compensation																															87,000
Value of shares issued for compensation | $																															$ 116,000
Shares holding term																															3 years
John Carruth [Member]
Number of shares issued for compensation						26,217
John Dolan [Member]
Number of shares issued for compensation						22,993
John Dolan [Member] | Settlement Agreement [Member]
Number of shares issued for compensation																															51,000
Value of shares issued for compensation | $																															$ 68,000
Shares holding term																															3 years
Gregory Cash [Member]
Number of shares issued for compensation						10,789
David Deming [Member]
Number of shares issued for compensation						10,711
Robert Rudelius [Member]
Number of shares issued for compensation						10,627
Randy Meyer [Member]
Number of shares issued for compensation						10,550
Jim Martin [Member]
Number of shares issued for compensation						9,302
Scott Johnson [Member]
Number of shares issued for compensation						9,300
Joseph Jasper [Member]
Number of shares issued for compensation						9,209
David Masters [Member]
Number of shares issued for compensation						8,935
Three Directors [Member]
Conversion of notes | $							$ 25,382
Debt Principal | $							25,000
Accrued interest | $							$ 382
Conversion price | $ / shares							$ 1.02
Number of shares issued for conversion							25,003
Number of shares issued for conversion, value | $							$ 25,383
Randall Meyer [Member] | Settlement Agreement [Member]
Number of shares issued for compensation																															143,952
Value of shares issued for compensation | $																															$ 191,936
Shares holding term																															3 years
Former Employee [Member] | Settlement Agreement [Member]
Number of shares issued for compensation																															42,014
Value of shares issued for compensation | $																															$ 80,029
One Shareholder [Member]
Number of stock sold															90,000
Value of stock sold | $															$ 100,000
One Investor [Member] | Warrants [Member]
Warrants to purchase shares of common stock																						10,000										10,000
Warrant to purchase of common stock, value | $																						$ 17,291										$ 17,291
Warrants exercise price | $ / shares																						$ 4										$ 4
Warrants exercise term																						3 years										3 years
Directors, Officers and Consultants [Member] | Warrants [Member]
Warrants to purchase shares of common stock																	72,596		72,596								72,596			72,596
Warrant to purchase of common stock, value | $																	$ 160,307		$ 160,307								$ 160,307			$ 160,307
Directors, Officers and Consultants [Member] | Warrants [Member] | Minimum [Member]
Warrants exercise price | $ / shares																	$ 1.40		$ 1.40								$ 1.40			$ 1.40
Directors, Officers and Consultants [Member] | Warrants [Member] | Maximum [Member]
Warrants exercise price | $ / shares																	1.60		1.60								1.60			1.60
Directors, Officers and Consultants [Member] | Warrants [Member] | Weighted Average [Member]
Warrants exercise price | $ / shares																	$ 1.52		$ 1.52								$ 1.52			$ 1.52
Accredited Investors [Member] | One Share of Common Stock and 1/2 Warrant Share [Member] | Warrants [Member]
Number of shares issued for compensation																												20,000
Warrants to purchase shares of common stock												40,000											40,000					40,000			40,000
Warrant to purchase of common stock, value | $												$ 104,000											$ 104,000					$ 104,000			$ 104,000
Fair value of warrants | $																												$ 34,609
Warrants exercise price | $ / shares												$ 4											$ 4					$ 4			$ 4
Warrants exercise term												3 years											3 years					3 years			3 years
Share price per share | $ / shares												$ 2.60											$ 2.60					$ 2.60			$ 2.60
2020 Equity Incentive Plan [Member]
Number of shares authorized									1,000,000
Expiration date									Jul. 10, 2030
Shares issued
2020 Equity Incentive Plan [Member] | Nonemployee Director [Member]
Maximum number of shares per employee									10,000

Common Stock and Warrants - Sch

Common Stock and Warrants - Schedule of Warrant Activity (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Mar. 31, 2020
Number of Warrants, Outstanding, Beginning Balance	1,225,295	954,745
Number of Warrants, Granted		476,425
Number of Warrants, Cashless warrant exercises	(116,125)	(84,375)
Number of Warrants, Expired	(22,500)	(22,500)
Number of Warrants, Canceled		(99,000)
Number of Warrants, Issued in conjunction with convertible debt	158,036
Number of Warrants, Sold for cash	10,000
Number of Warrants, Issued and granted	72,596
Number of Warrants, Exercised for cash	(202,499)
Number of Warrants, Outstanding, Ending Balance	1,124,803	1,225,295
Weighted-Average Exercise Price, Outstanding, Beginning Balance	$ 2.12	$ 2.20
Weighted-Average Exercise Price, Granted		2.07
Weighted-Average Exercise Price, Cashless warrant exercises	1.49	1.27
Weighted-Average Exercise Price, Expired	7.56	2.22
Weighted-Average Exercise Price, Canceled		2.32
Weighted-Average Exercise Price, Issued in conjunction with convertible debt	1.40
Weighted-Average Exercise Price, Sold for cash	4
Weighted-Average Exercise Price, Issued and granted	1.52
Weighted-Average Exercise Price, Exercised for cash	2.22
Weighted-Average Exercise Price, Outstanding, Ending Balance	$ 1.99	$ 2.12
Warrants Exercisable, Outstanding, Beginning Balance	1,018,092	758,759
Warrants Exercisable, Outstanding, Ending Balance	1,100,306	1,018,092
Weighted-Average Exercisable Price, Outstanding, Beginning Balance	$ 2.13	$ 2.16
Weighted-Average Exercisable Price, Outstanding, Ending Balance	$ 1.87	$ 2.13

Common Stock and Warrants - S_2

Common Stock and Warrants - Schedule of Range of Warrant Prices (Details) - $ / shares	9 Months Ended
	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Warrant [Member]
Number of Warrants, Outstanding	1,124,803
Weighted-Average Exercise Price, outstanding	$ 1.99	$ 2.12		$ 2.20
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 26 days
Number of Warrants, Exercisable	1,100,306	1,018,092		758,759
Weighted-Average Exercise Price, Exercisable	$ 1.87	$ 2.13		$ 2.16
Minimum [Member] | Warrant [Member]
Range of Warrant Exercise Price	1.20		$ 15.56
Maximum [Member] | Warrant [Member]
Range of Warrant Exercise Price	$ 15.56		$ 1.20
Range One [Member]
Number of Warrants, Outstanding	696,190
Range One [Member] | Warrant [Member]
Weighted-Average Exercise Price, outstanding	$ 1.36
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 7 months 10 days
Number of Warrants, Exercisable	850,568
Weighted-Average Exercise Price, Exercisable	$ 1.34
Range One [Member] | Minimum [Member]
Range of Warrant Exercise Price	1.20
Range One [Member] | Maximum [Member]
Range of Warrant Exercise Price	$ 2
Range Two [Member]
Number of Warrants, Outstanding	320,438
Range Two [Member] | Warrant [Member]
Weighted-Average Exercise Price, outstanding	$ 2.39
Weighted-Average Remaining Contractual Life (Years), Outstanding	3 years 8 months 2 days
Number of Warrants, Exercisable	134,813
Weighted-Average Exercise Price, Exercisable	$ 2.62
Range Two [Member] | Minimum [Member]
Range of Warrant Exercise Price	2.01
Range Two [Member] | Maximum [Member]
Range of Warrant Exercise Price	$ 4
Range Three [Member]
Number of Warrants, Outstanding	108,175
Range Three [Member] | Warrant [Member]
Weighted-Average Exercise Price, outstanding	$ 4.94
Weighted-Average Remaining Contractual Life (Years), Outstanding	1 year 9 months
Number of Warrants, Exercisable	114,925
Weighted-Average Exercise Price, Exercisable	$ 4.91
Range Three [Member] | Minimum [Member]
Range of Warrant Exercise Price	4.01
Range Three [Member] | Maximum [Member]
Range of Warrant Exercise Price	$ 10

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 09, 2021	Jan. 29, 2021	Jan. 15, 2021	Jan. 04, 2021	Oct. 30, 2020	Jul. 24, 2020	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Number of shares issued							991,014	652,466
Accrued interest									$ 6,981
John Lai [Member]
Number of shares issued					42,188
Warrants exercise price					$ 1.33
One Warrant Holder [Member]
Number of shares issued						15,257
Warrants exercise price						$ 1.20
Subsequent Event [Member]
Debt conversion amount			$ 50,000
Debt Principal			205
Accrued interest			$ 17,379
Conversion price			$ 2.89
Subsequent Event [Member] | John Lai [Member]
Number of shares issued				38,516
Cashless warrant exercises, shares				42,188
Warrants exercise price				$ 1.33
Subsequent Event [Member] | One Warrant Holder [Member]
Warrants exercise price	$ 4.44	$ 1.20
Warrants exercised shares	9,000	17,188
Warrant exercised outstanding	5,163	15,629